tiprankstipranks
Trending News
More News >
Xvivo Perfusion AB (XVIPF)
OTHER OTC:XVIPF

Xvivo Perfusion AB (XVIPF) Stock Statistics & Valuation Metrics

Compare
11 Followers

Total Valuation

Xvivo Perfusion AB has a market cap or net worth of $949.75M. The enterprise value is $4.35B.
Market Cap$949.75M
Enterprise Value$4.35B

Share Statistics

Xvivo Perfusion AB has 31,499,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,499,470
Owned by Insiders
Owned by Institutions

Financial Efficiency

Xvivo Perfusion AB’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 3.40%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)3.40%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee4.26M
Profits Per Employee1.04M
Employee Count193
Asset Turnover0.34
Inventory Turnover0.91

Valuation Ratios

The current PE Ratio of Xvivo Perfusion AB is 89.46. Xvivo Perfusion AB’s PEG ratio is 2.41.
PE Ratio89.46
PS Ratio0.00
PB Ratio3.78
Price to Fair Value7.14
Price to FCF-52.41
Price to Operating Cash Flow193.97
PEG Ratio2.41

Income Statement

In the last 12 months, Xvivo Perfusion AB had revenue of 822.41M and earned 172.18M in profits. Earnings per share was 5.47.
Revenue822.41M
Gross Profit616.41M
Operating Income88.35M
Pretax Income199.95M
Net Income172.18M
EBITDA272.97M
Earnings Per Share (EPS)5.47

Cash Flow

In the last 12 months, operating cash flow was 94.45M and capital expenditures -19.70M, giving a free cash flow of 74.75M billion.
Operating Cash Flow94.45M
Free Cash Flow74.75M
Free Cash Flow per Share2.37

Dividends & Yields

Xvivo Perfusion AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.11
52-Week Price Change-21.90%
50-Day Moving Average31.66
200-Day Moving Average38.66
Relative Strength Index (RSI)51.58
Average Volume (3m)46.00

Important Dates

Xvivo Perfusion AB upcoming earnings date is Oct 23, 2025, TBA (Confirmed).
Last Earnings DateJul 11, 2025
Next Earnings DateOct 23, 2025
Ex-Dividend Date

Financial Position

Xvivo Perfusion AB as a current ratio of 4.58, with Debt / Equity ratio of 0.70%
Current Ratio4.58
Quick Ratio3.30
Debt to Market Cap0.00
Net Debt to EBITDA-1.40
Interest Coverage Ratio70.12

Taxes

In the past 12 months, Xvivo Perfusion AB has paid 27.77M in taxes.
Income Tax27.77M
Effective Tax Rate0.14

Enterprise Valuation

Xvivo Perfusion AB EV to EBITDA ratio is 55.03, with an EV/FCF ratio of -183.50.
EV to Sales18.27
EV to EBITDA55.03
EV to Free Cash Flow-183.50
EV to Operating Cash Flow134.98

Balance Sheet

Xvivo Perfusion AB has $315.87M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -$315.87M billion.
Cash & Marketable Securities$315.87M
Total Debtkr0.00
Net Cash-$315.87M
Net Cash Per Share-$10.03
Tangible Book Value Per Share$23.79

Margins

Gross margin is 71.51%, with operating margin of 10.74%, and net profit margin of 20.94%.
Gross Margin71.51%
Operating Margin10.74%
Pretax Margin24.31%
Net Profit Margin20.94%
EBITDA Margin33.19%
EBIT Margin24.47%

Analyst Forecast

The average price target for Xvivo Perfusion AB is $34.03, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$34.03
Price Target Upside9.95% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis